JP2019515026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515026A5 JP2019515026A5 JP2019503398A JP2019503398A JP2019515026A5 JP 2019515026 A5 JP2019515026 A5 JP 2019515026A5 JP 2019503398 A JP2019503398 A JP 2019503398A JP 2019503398 A JP2019503398 A JP 2019503398A JP 2019515026 A5 JP2019515026 A5 JP 2019515026A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C**1*(C2)C2CC1 Chemical compound C**1*(C2)C2CC1 0.000 description 3
- HCOFVGDDABFNJB-UHFFFAOYSA-N CCCCc1ccccc1NCC Chemical compound CCCCc1ccccc1NCC HCOFVGDDABFNJB-UHFFFAOYSA-N 0.000 description 1
- GDGULTXZDPTNNZ-NSCUHMNNSA-N COC(/C=C/c1cc(F)c(C=O)c(F)c1)=O Chemical compound COC(/C=C/c1cc(F)c(C=O)c(F)c1)=O GDGULTXZDPTNNZ-NSCUHMNNSA-N 0.000 description 1
- RSVHQPLZYJNYJP-SVMLNYGMSA-N C[C@H](C1)N2C3(CC4C3)C4c3cc(/C=C/C(OC)=O)cc(F)c3[C@@H]2c2c1c(cccc1)c1[nH]2 Chemical compound C[C@H](C1)N2C3(CC4C3)C4c3cc(/C=C/C(OC)=O)cc(F)c3[C@@H]2c2c1c(cccc1)c1[nH]2 RSVHQPLZYJNYJP-SVMLNYGMSA-N 0.000 description 1
- BVOINHANKYWPHF-OPGSHWCFSA-N C[C@H](Cc1c[nH]c2ccccc12)NC1(C2)CC2C1 Chemical compound C[C@H](Cc1c[nH]c2ccccc12)NC1(C2)CC2C1 BVOINHANKYWPHF-OPGSHWCFSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021127863A JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317254P | 2016-04-01 | 2016-04-01 | |
| US62/317,254 | 2016-04-01 | ||
| PCT/US2017/024809 WO2017172957A1 (en) | 2016-04-01 | 2017-03-29 | Estrogen receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127863A Division JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515026A JP2019515026A (ja) | 2019-06-06 |
| JP2019515026A5 true JP2019515026A5 (cg-RX-API-DMAC7.html) | 2020-05-07 |
| JP6926189B2 JP6926189B2 (ja) | 2021-08-25 |
Family
ID=59966438
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503398A Active JP6926189B2 (ja) | 2016-04-01 | 2017-03-29 | エストロゲン受容体調節薬 |
| JP2021127863A Pending JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127863A Pending JP2021176911A (ja) | 2016-04-01 | 2021-08-04 | エストロゲン受容体調節薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190142811A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3442971B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6926189B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220071293A (cg-RX-API-DMAC7.html) |
| CN (4) | CN113717170A (cg-RX-API-DMAC7.html) |
| AR (1) | AR108011A1 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2017242027B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3017388C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2991862T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL285318B (cg-RX-API-DMAC7.html) |
| MX (2) | MX392461B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2738646C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201807708SA (cg-RX-API-DMAC7.html) |
| TW (2) | TW202235418A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017172957A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102479822B1 (ko) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| KR20220071293A (ko) | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| IL272875B2 (en) | 2017-09-11 | 2023-10-01 | Recurium Ip Holdings Llc | Continuous flow processes for the preparation of bicyclic compounds |
| EP3709997A1 (en) * | 2017-11-16 | 2020-09-23 | Novartis AG | Pharmaceutical combination comprising lsz102 and ribociclib |
| CN114929696A (zh) * | 2019-05-24 | 2022-08-19 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
| KR20220044528A (ko) * | 2019-08-06 | 2022-04-08 | 리커리엄 아이피 홀딩스, 엘엘씨 | 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제 |
| AU2020380211A1 (en) * | 2019-11-04 | 2022-05-19 | Recurium Ip Holdings, Llc | Salts and forms of an estrogen receptor modulator |
| CA3165477A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| JP2023507797A (ja) * | 2019-12-20 | 2023-02-27 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 組み合わせ |
| EP4069225A4 (en) * | 2019-12-20 | 2023-12-27 | Recurium IP Holdings, LLC | COMBINATIONS |
| IL294067A (en) * | 2019-12-20 | 2022-08-01 | Recurium Ip Holdings Llc | Combinations |
| WO2021127042A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| WO2021216671A1 (en) * | 2020-04-22 | 2021-10-28 | Recurium Ip Holdings, Llc | Preparation of an selective estrogen receptor degrader |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| AU2021343525A1 (en) * | 2020-09-20 | 2023-05-18 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
| WO2022133446A1 (en) * | 2020-12-16 | 2022-06-23 | Recurium Ip Holdings, Llc | Combinations |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| WO2023283329A1 (en) * | 2021-07-08 | 2023-01-12 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU679635B2 (en) | 1994-03-11 | 1997-07-03 | Eli Lilly And Company | Method for treating 5HT-2B receptor related conditions |
| GB9604996D0 (en) | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| JP2005508968A (ja) | 2001-10-19 | 2005-04-07 | トランス テック ファーマ，インコーポレイテッド | ＰＴＰ阻害剤としてのβ−カルボリン誘導体 |
| US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US20080103164A1 (en) | 2004-08-02 | 2008-05-01 | Kristjan Gudmundsson | Useful compounds for hpv infection |
| WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| US20100158858A1 (en) | 2007-04-13 | 2010-06-24 | Liangxian Cao | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| US20120202801A1 (en) * | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| MX373926B (es) * | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| RU2540330C2 (ru) * | 2009-07-28 | 2015-02-10 | Оно Фармасьютикал Ко., Лтд. | Бициклическое соединение и его применение для медицинских целей |
| WO2011088025A1 (en) | 2010-01-15 | 2011-07-21 | Merck Sharp & Dohme Corp. | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| NZ602266A (en) * | 2010-02-11 | 2014-05-30 | Bristol Myers Squibb Co | Macrocycles as factor xia inhibitors |
| WO2011103487A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| JP5835236B2 (ja) * | 2011-01-27 | 2015-12-24 | 小野薬品工業株式会社 | 二環式化合物およびその医薬用途 |
| CN102432608B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法 |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| MX353578B (es) * | 2011-12-31 | 2018-01-19 | Beigene Ltd | Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp). |
| CA2863413A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| US9499538B2 (en) | 2012-03-20 | 2016-11-22 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| LT2872482T (lt) | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
| ES2671516T3 (es) | 2013-02-19 | 2018-06-06 | Novartis Ag | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno |
| MX2015011132A (es) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
| UY35590A (es) * | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| EP3089747A1 (en) | 2013-12-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| CN104693211A (zh) | 2013-12-10 | 2015-06-10 | 南京明德新药研发股份有限公司 | 作为抗病毒剂的咪唑衍生物及其制药用途 |
| TW201613891A (en) * | 2014-02-12 | 2016-04-16 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
| WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| CA2948077A1 (en) | 2014-05-16 | 2015-11-19 | Actelion Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
| MX388871B (es) | 2014-06-27 | 2025-03-20 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
| WO2016054971A1 (zh) | 2014-10-09 | 2016-04-14 | 南京明德新药研发股份有限公司 | 羟基嘌呤类化合物及其应用 |
| CN107709290B (zh) | 2015-04-21 | 2023-02-28 | Gtx公司 | 选择性雄激素受体降解剂(sard)配体和其使用方法 |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10087191B2 (en) * | 2015-06-16 | 2018-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
| JP6592197B2 (ja) | 2015-11-12 | 2019-10-16 | 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． | アクリル酸誘導体、製造方法、および医薬としてのその使用 |
| KR102479822B1 (ko) * | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| CN109310664A (zh) | 2016-06-10 | 2019-02-05 | 田纳西大学研究基金会 | 选择性雄激素受体降解剂(sard)配体和其使用方法 |
| WO2018001232A1 (zh) * | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| JP7050770B2 (ja) * | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| WO2018130124A1 (zh) | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
-
2017
- 2017-03-29 KR KR1020227016946A patent/KR20220071293A/ko not_active Ceased
- 2017-03-29 IL IL285318A patent/IL285318B/en unknown
- 2017-03-29 US US16/086,434 patent/US20190142811A1/en not_active Abandoned
- 2017-03-29 CN CN202111035485.4A patent/CN113717170A/zh active Pending
- 2017-03-29 CN CN202011582784.5A patent/CN112745316A/zh active Pending
- 2017-03-29 KR KR1020187030841A patent/KR102401841B1/ko active Active
- 2017-03-29 WO PCT/US2017/024809 patent/WO2017172957A1/en not_active Ceased
- 2017-03-29 CN CN202011582762.9A patent/CN112679495B/zh active Active
- 2017-03-29 JP JP2019503398A patent/JP6926189B2/ja active Active
- 2017-03-29 EP EP17776574.0A patent/EP3442971B1/en active Active
- 2017-03-29 IL IL295050A patent/IL295050A/en unknown
- 2017-03-29 AU AU2017242027A patent/AU2017242027B2/en active Active
- 2017-03-29 SG SG11201807708SA patent/SG11201807708SA/en unknown
- 2017-03-29 CN CN201780033815.1A patent/CN109311870B/zh active Active
- 2017-03-29 RU RU2018132037A patent/RU2738646C2/ru active
- 2017-03-29 MX MX2018011419A patent/MX392461B/es unknown
- 2017-03-29 ES ES17776574T patent/ES2991862T3/es active Active
- 2017-03-29 CA CA3017388A patent/CA3017388C/en active Active
- 2017-03-30 AR ARP170100788A patent/AR108011A1/es unknown
- 2017-03-30 TW TW110145253A patent/TW202235418A/zh unknown
- 2017-03-30 TW TW106110662A patent/TWI746535B/zh active
-
2018
- 2018-09-06 IL IL261654A patent/IL261654B/en unknown
- 2018-09-24 MX MX2022005780A patent/MX2022005780A/es unknown
-
2020
- 2020-05-05 US US16/866,900 patent/US11065233B2/en active Active
- 2020-05-05 US US16/866,995 patent/US10959989B2/en active Active
- 2020-05-05 US US16/867,017 patent/US11065234B2/en active Active
- 2020-12-22 AU AU2020294196A patent/AU2020294196B2/en active Active
-
2021
- 2021-07-06 US US17/305,369 patent/US20210330651A1/en not_active Abandoned
- 2021-08-04 JP JP2021127863A patent/JP2021176911A/ja active Pending
-
2022
- 2022-06-09 AU AU2022204025A patent/AU2022204025A1/en not_active Abandoned